Categories
Authors
Christian Schumacher (RSS) (95)
Florian Winkler (RSS) (7)
Site Admin (RSS) (2)
guestpost (RSS) (2)
Andrew Armstrong (RSS) (1)
Megan Nichols (RSS) (1)
Monthly Archives: March 2012
What is going on inside the e-cat machine ?
Rossi claims his e-cat device would use a secret catalyser to fuse hydrogen and nickel together to form copper. The excess energy would be released in the form of a gamma ray - Some insights about what could be possibly going on in the e-cat. Continue reading
Dirty Laundry Greenpeace campaign
Greenpeace started a campaign to stop the release of hazardous chemicals used in textile manufacturing, associated with the suppliers of major international clothing brands. Continue reading
Transmutations – the alchemists are back
Alchemists are back - transmutation of elements under mild conditions as claimed by cold fusion scientists Continue reading
Dark matter defies explanation
Dark matter core, left behind from wreck between massive clusters of galaxies, defies explanation Continue reading
Mr. Rossi´s e-cat patent and black box approach
We analyzed Mr Rossi´s e-cat patent. We believe the patent lacks sufficient disclosure, is of speculative nature, the secretive black box approach is a risk for disallowance of the patent. Continue reading
What happened to Cold Fusion ?
after 23 years of research, there is robust evidence for nuclear fusion reactions initiated at low temperatures. The blog reports on latest development, pros and cons of the this exiting area of research. Continue reading
Rossi expects 5-year wait for US Patent on cold fusion
Italian inventor Rossi who claims having built a low energy fusion device called E-cat, expects it take upwards of five years for the US patents to be granted. Continue reading
Neutrino retest shows Einstein was right
CERN´s neutrino experiment was wrongly measured. Einstein was right. Continue reading
Blocking HIV’s Attack
scientists have rid one man of HIV by preventing the virus from entering certain immune cells Continue reading
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma
India has invoked its compulsory licensing rules for the first time to make and sell a version of Bayer's cancer drug Nexavar despite the fact that Nexavar is still on patent.
We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ? Continue reading